Amicogen, a bio-materials and healthcare specialized company (CEO Pyo Jjeo), announced on the 9th that it will hold an extraordinary general meeting of shareholders at 10 a.m. on February 26 at its Incheon Songdo factory. The main agenda of this shareholders' meeting will be the appointment of outside directors and inside directors.
The candidates are recommended by the shareholder coalition, and the meeting will decide on the appointment of one new outside director and one new inside director. Amicogen convened the extraordinary general meeting of shareholders in response to shareholders' requests and expressed its intention to listen to shareholders' voices and realize more transparent and neutral management in the future through this opportunity.
An Amicogen official said, “Going forward, the company will actively expand shareholder-friendly policies and strive to communicate with the market to protect shareholders' rights and promote the company's mid- to long-term growth. The candidates recommended this time are expected to contribute significantly to the company's management as they possess expertise in the fields of law and medicine.”
Recently, Amicogen has successfully localized key materials for biopharmaceutical production, contributing to strengthening the competitiveness of the domestic bio industry. In addition, by selling and liquidating non-core subsidiaries, it is improving its financial structure and focusing its capabilities on the media and resin businesses to pursue sustainable growth.
Meanwhile, through the decisions made at this shareholders' meeting, including the appointment of directors, Amicogen plans to establish a governance structure that meets global standards, closely cooperate with shareholders based on transparency and trust, and open new possibilities in the global market through innovation and growth.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
